All News

IL17

Expanding the IL-17 Therapeutic Landscape

Adela Castro, MD

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

Read Article
lupus SLE

Social Determinants of Health in SLE

EurekAlert!

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.

Read Article
Puzzle pieces

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

Read Article
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Dr. John Cush RheumNow ( View Tweet)

Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA 🔹️Associated with type of initial symptoms (shorter in peripheral) POS0909 #EULAR2025 @rheumnow https://t.co/3BMYFxbKiq

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ⬇️BVAS over 1 yr in all groups #GPA #MPA #eGPA 5yr survival not = over time ⬆️survival in eGPA & GPA vs MPA #POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS

Links:

Janet Pope Janetbirdope ( View Tweet)
Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived phenotypes map (independent of ACPA): - to broad histopath - to MTX response Omics is good, but still need to do the simple stuff better! #EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso

Links:

David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC

Links:

Dr. John Cush RheumNow ( View Tweet)

Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI

Links:

David Liew drdavidliew ( View Tweet)
#vagal & #splenic #nerves most studied In #immune #system interaction #PNS can detect #inflammation use in #D2T #RA w active disease ? Key factors in #neurostimulation - many #EULAR2025 @RheumNow @eular_org #D2T in #RA session https://t.co/tCgpGtI5z2

Links:

Janet Pope Janetbirdope ( View Tweet)
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases? A thread 🧵👇🏼 @RheumNow #EULAR2025 https://t.co/KLZN9MvcFy

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Interesting debate today #EULAR2025 about medical cannabis - where relative harms have come up. Would you rather be addicted to prescription opioids or recreational cannabis? (not going to argue about cannabis addiction - let’s say social impact is equal) @RheumNow

David Liew drdavidliew ( View Tweet)

#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts RESSET RCT +RA #RCT w #VNS But low response with stat significance ACR20 1/4 sham vs 1/3 VNS Would add on to new SoC? 🤔 #EULAR2025 @RheumNow #eular_org #D2T- RA-session https://t.co/tR1pLPBr74

Links:

Janet Pope Janetbirdope ( View Tweet)
So we used to get taught about bimodal age distribution of RA onset - young people and old people. Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity Global Burden of Disease data #EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy

Links:

David Liew drdavidliew ( View Tweet)
Even after having things laid out in a great debate, rheumatologists remain unconvinced by medical cannabis #EULAR2025 @RheumNow https://t.co/xMTvngS5N1

Links:

David Liew drdavidliew ( View Tweet)
cool stuff at #EULAR2025 RESET #RCT - #vagal #nerve #stimulation #VNS vs sham in #RA w 1or >1 #bDMARD-IR N=242 D/C bDMARD, on #csDMARD #RA 12 yrs, 10SJC 12TJC 2.6 b/tsDMARD failure Wk12 EULAR good/mod response 61v 42% Sham▶️goes VNS ✅data= @RheumNow @eular_org abst#OP190

Janet Pope Janetbirdope ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Dr. John Cush RheumNow ( View Tweet)

GRAPPA defines : - D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs) - CM(complex to manage)-PsA (adds pain, comorbidity, complexity). A needed framework to improve trial design & real-world care. Do these definitions fit your clinic? #OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA

Links:

Jiha Lee JihaRheum ( View Tweet)
Rheumatology #AI to optimize rheumatology triage. Only 53 percent correlation between the AIs diagnosis with rheumatologists final diagnosis. Not sure if we want 47 percent pts to drop off...without a chance for diagnosis? #POS0883 #EULAR2025 @RheumNow https://t.co/UWsCHG00t1

Links:

Bella Mehta bella_mehta ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×